S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.
By W. Koizumi, H. Narahara, T. Hara, A. Takagane, T. Akiya, M. Takagi, K. Miyashita, T. Nishizaki, O. Kobayashi, W. Takiyama and 7 more. The Lancet Oncology, 2008
1,833 citations recorded by the source corpus.
Subfields: Cancer Research, Pulmonary and Respiratory Medicine, Surgery
View Paper: https://www.semanticscholar.org/paper/0f21aaeaf904a8af470242b66030bb8597ef5f76
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Pulmonary and Respiratory Medicine
In Surgery
Citations in the corpus
- Japanese Gastric Cancer Treatment Guidelines 2021 (6th edition) (2022, background): “A combination of S-1 and cisplatin (SP) is the standard of care (the recommended regimen) based on the results of two phase III trials conducted in Japan (JCOG 9912 trial [48] and SPIRITS trial [49]).”
- Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. (2009, background): “Also of interest is the recent SPIRITS trial, which reported an improved outcome in terms of OS with oral S-1–cisplatin compared with S-1 alone in the first-line treatment of AGC [18].”
- Japanese gastric cancer treatment guidelines 2018 (5th edition) (2020, background): “A combination of S-1 and cisplatin (SP) is the standard of care (the recommended regimen) based on the results of two phase III trials conducted in Japan (JCOG 9912 trial [41] and SPIRITS trial [42]) (evidence level A).”
- Cisplatin: The first metal based anticancer drug. (2019, background): “Cisplatin is not limited for treatment of testicular, ovarian and lung cancers, it is broadly used for treatment of childhood brain tumors [117], gastric cancer [118], leukemia [119], anal cancer [120], etc.”